• 1
    Grundy SM, Cleeman JI, Merz CN et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227239.
  • 2
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults final report. Circulation, 106, 31433421.
  • 3
    Chong PH (2002) Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Annals of Pharmacotherapy, 36, 19071917.
  • 4
    Zhou Z, Rahme E, Pilote L (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention American Heart Journal, 151, 273281.
  • 5
    Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. British Medical Journal, 326, 14231429.
  • 6
    Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors (Statins). VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Available at: (accessed 24 December 2006).
  • 7
    Oregon Health Resources Commission HMG-CoA Reductase Inhibitors (Statins) Subcommittee Report, 3 edn. Oregon Health Resources Commission. Available at: (accessed 24 December 2006).
  • 8
    Cochrane Handbook for Systematic Reviews of Interventions 4·2·5 Available at: (accessed 24 December 2006).
  • 9
    Undertaking Systematic Reviews of Research on Effectiveness Center for Review and Dissemination. Available at: (accessed 24 December 2006).
  • 10
    Harris RP, Helfand M, Woolf SH et al. (2001) Current methods of the US preventive services task force: a review of the process. American Journal of Preventive Medicine, 20(Suppl.), 2135.
  • 11
    Thompson PD, Clarkson PM, Rosenson RS (2006) An assessment of statin safety by muscle experts. American Journal of Cardiology, 97, 69C76C.
  • 12
    Cannon CP, Braunwald E, McCabe CH et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350, 14951504.
  • 13
    Pedersen TR, Faergeman O, Kastelein JJP et al. (2005) High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 294, 24372445.
  • 14
    Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). American Journal of Cardiology, 81, 582587.
  • 15
    Jones PH, Davidson MH, Stein EA et al. (2003) Comparison of the efficacy and safety of rosuvastatin vs. atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). American Journal of Cardiology, 92, 152160.
  • 16
    Zhou Z, Rahme E, Abrahamowicz M et al. (2005) Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ: Canadian Medical Association Journal, 172, 11871194.
  • 17
    Silva MA, Swanson AC, Gandhi PJ, Tataronis GR (2006) Statin-related adverse events: a meta-analysis. Clinical Therapeutics, 28, 2635.
  • 18
    Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH (2005) The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation, 111, 30513057.
  • 19
    Davidson MH, Clark JA, Glass LM, Kanumalla A (2006) Statin safety: an appraisal from the adverse event reporting system. American Journal of Cardiology, 97, 32C43C.
  • 20
    Jacobson TA (2006) Statin safety: lessons from new drug applications for marketed statins. American Journal of Cardiology, 97, 44C51C.